The pathogenesis of central nervous system disease during human immunodeficiency virus type 1 (HIV-1) infection revolves around productive viral infection of brain macrophages and microglia. Neuronal losses in the cortex and subcortical gray matter accompany macrophage infection. The question of how viral infection of brain macrophages ultimately leads to central nervous system (CNS) pathology remains unanswered. Our previous work demonstrated high-level production of tumor necrosis factor alpha, interleukin 1 , arachidonic acid metabolites, and platelet-activating factor (PAF) from HIV-infected monocytes and astroglia
Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system (CNS) results in cognitive and motor abnormalities in a majority of infected individuals. HIV-1-associated dementia or AIDS dementia complex (ADC), a devastating complication of direct viral infection of the brain, arguably represents one of the most severe and significant clinical manifestations of HIV infection (6, 13, 16, 26, 43) . The pathological hallmarks coincident with cognitive and motor dysfunctions include HIV-1 infection of brain macrophages, microglia, and multinucleated giant cells; astrocyte proliferation; and neuronal loss in discrete areas of the retina, neocortex, and subcortical brain (14, 18, 29, 40, 49, 50, 53, 59, 60) . Interestingly, this disease complex is most prevalent in virus-infected children (6) .
The molecular mechanisms governing neurologic dysfunction during HIV-1 infection of the brain remain an enigma. No laboratory has convincingly demonstrated HIV-1 mRNA or p24 antigens in neurons or oligodendrocytes within virusinfected brain tissue. How does HIV-1 cause neuronal loss when neurons are not infected and perhaps only a small number of macrophages support productive viral replication (13, 17, 40) ? Indeed, secretory products from HIV-1-infected macrophages are the likely source of neurotoxic activities. Neuronal death can occur soon after exposure to culture fluids from HIV-1-infected monocytes. Monocyte production of neurotoxic factors appears to require HIV-1 infection (21, 47) , monocyte activation, and astroglia and/or neuronal monocyte interactions (2, 12, 17, 20, 52) . HIV-1 gene products also affect neuronal viability. Picomolar amounts of HIV-1 gpl20 added to mixed microglial-neuronal cells in the presence of sublethal concentrations of glutamate are toxic to rat retinal ganglion cells (10, 11, (33) (34) (35) . This toxicity is associated with increased neuronal Ca2' and is reversed by calcium channel or Nmethyl-D-aspartate (NMDA) antagonists (33) (34) (35) .
Our recent work has demonstrated that coculture of HIV-1-infected monocytes and human astrocytoma cell lines induces cytokines, arachidonic acid metabolites, and plateletactivating factor (PAF) from virus-infected monocytes (20) . Astroglia cells serve to activate macrophages for their production of these neurotoxic factors (17) . Our initial studies, however, did not provide evidence that any or all of the factors are neurotoxins or determine whether they play a biologically important role in neurological disease. The purpose of the present study was to identify PAF as a candidate HIV-1 neurotoxin and to provide a conceptual framework for how "putative" HIV-1 neurotoxins are identified. PAF is produced within cocultures of HIV-1-infected monocytes and astroglia and is present in the cerebrospinal fluid (CSF) of HIV-infected patients during neurologic dysfunction. PAF added to primary human or rat neurons at levels approximating those found in the CSF of HIV-1-infected patients produces dose-dependent neurotoxicity. NMDA receptor uncompetitive antagonists MK-801 and memantine (4, 22, 35, 39) block PAF-mediated neurotoxicity. These findings, taken together, provide insights into the pathobiology of ADC and new ideas for therapeutic interventions for neurological impairments associated with HIV-1 infection.
MATERIALS AND METHODS
HIV-1 infection of monocytes. Monocytes were recovered from peripheral blood mononuclear cells of HIV-and hepatitis B-seronegative donors after leukapheresis and purified by countercurrent centrifugal elutriation. Cell suspensions were >98% monocytes by criteria of cell morphology on Wrightstained cytosmears, by granular peroxidase, and by nonspecific esterase (15, 19) . Cells were cultured as adherent monolayers (106/ml in 24-mm-diameter plastic culture wells) in Dulbecco modified Eagle medium (Sigma, St. Louis, Mo.) with recombinant human macrophage colony-stimulatory factor (Genetics Institute, Cambridge, Mass.). The human brain astroglia tumor-derived cell line U251 MG, a generous gift from D. Bigner, was utilized in cocultivation assays with HIV-1-infected monocytes as described previously (20) . These cells were grown as adherent monolayers in Dulbecco modified Eagle medium (Sigma)-10% heat-inactivated fetal calf serum (Sigma)-50 ,ug of gentamicin per ml.
Monocytes were exposed to HIV-1ADA (accession number M60472) (42) at a multiplicity of infection of 0.01 infectious virions per target cell (19, 57) . The viral inocula were free of mycoplasma contamination (Mycoplasma Detection Kit III; Geneprobe, San Diego, Calif.). Human macrophage colonystimulating factor-treated monocytes were cultured as adherent monolayers 7 to 10 days prior to use as viral target cells. Under these conditions, 10 to 20% of the monocytes are productively infected 7 days after HIV-1 inoculation (27) . All cultures were refed with fresh medium every 2 to 3 days. Reverse transcriptase activity was determined in culture fluids added to a reaction mixture of Nonidet P-40 (Sigma), poly(rA)-oligo(dT) (Pharmacia, Piscataway, N.J.), dithiothreitol (Pharmacia), MgCl2, and [oa-32P]dTTP (400 Ci/mmol; Amersham Corp., Arlington Heights, Ill.) for 24 h at 37°C. The mixture was applied to chromatography paper, air dried, and washed five times in 0.3 M NaCl-0.03 M sodium citrate (pH 7.4) and twice in 95% ethanol. The paper was dried and cut, and the radioactivity was counted by liquid scintillation spectroscopy (27 (26) .
b Pediatric patients were assigned "best-approximation" ADC stages to conform with the adult data. All of the subjects were male.
recovery, based on inclusion of internal standards of [3H]PAF during extraction. The material was dissolved in 1.2 ml of methanol and aliquoted into 0.1-, 0.4-, and 0.6-ml fractions. These were dried by vacuum centrifugation (Savant Instruments, Inc., Farmingdale, N.Y.), and PAF was quantitated by radioimmunoassay (E. I. Du Pont de Nemours & Co., Boston, Mass.). The detectable levels of PAF in these assays were 30 to 1,200 pg/ml (20 (36) . With the retrograde labeling technique, the ganglion cell neurons could be specifically identified by the presence of the blue fluorescent label, even following dissociation from the retina and placement in culture, as previously described (31, 36) . The (45) . Previous studies using high-pressure liquid chromatographic analysis showed that these retinal cultures contain approximately 25 jiM glutamate (an NMDA receptor agonist) and 15 jiM glycine (an NMDA receptor coagonist), but by themselves these levels of the amino acids are not neurotoxic in this system (35) .
The ability of retinal ganglion cells to take up and cleave fluorescein diacetate to fluorescein was used as an index of their viability and lack of injury, as described previously (17, 31 Our previous work demonstrated that tumor necrosis factor alpha (TNF-oz), interleukin 1B, arachidonic acid metabolites, and PAF are produced during interactions between HIVinfected monocytes and astroglia tumor cell lines. These factors predict neurotoxicity (20) . The contribution that each of these factors made to neurotoxicity was not demonstrated. Therefore, we performed a series of experiments to determine whether PAF is a neurotoxin associated with HIV-1 infection and neurological disease.
PAF levels were examined by radioimmunoassay in HIV-1-infected cell cultures. Monocytes were infected with HIVlADA at a multiplicity of infection of 0.01 for 7 days then added in a 1:1 cell-to-astroglia ratio (U251 MG cells). Methanol extracts of cells were prepared during monocyte-astroglial coculture at 1, 3, 6, 12, 20, and 30 min. As shown in Fig. 1 (Tables 1 and 2 ). Neurologic dysfunction, defined by the clinical parameters of the ADC, was scored on a scale of 0 to 4. Immunosuppression was measured by determining numbers of CD4+ T cells in blood. Six of the 23 patients were children, with ages ranging from 7 months to 10 years. In the pediatric group, three of six children had elevated PAF levels (152 to 322 pg/ml), correlating with neurologic dysfunction and immunosuppression ( Fig. 2 (Fig. 4) . At (50, 300 , and 1,250 pg/ml [97 pM, 557 pM, and 2.3 nM, respectively]). The cultures were washed, fixed in paraformaldehyde, and subjected to PGP 9.5 immunocytochemical labeling. Neuronal cell counting was performed as described in Materials and Methods. Observers were blinded to the treatment groups. Each neuronal cell count shown represents the mean of .15 microscopic fields selected from four replicates ± SEM. Symbols: *, P < 0.0001, control versus PAF at 300 pg/mI; +, P < 0.0001, control versus PAF at 1,250 pg/ml. was partially blocked by coincubation with 10 ,uM MK-801 (Fig. 5A ). The numbers of neurons treated with both PAF and MK-801 were 80% of the numbers of untreated control observed following addition of c-PAF and was largely prevented by the specific NMDA antagonist MK-801 or memantine (each at 6 ,uM) (Fig. 5B) . Thus, PAF-induced neurotoxicity was seen in both human and rat neuronal cell culture systems.
DISCUSSION
Productive HIV infection of the brain occurs in brain macrophages and microglia. Cognitive and motor dysfunction occurs, as well as neuronal loss in infected brain tissue. HIV-1-infected brain macrophages and microglia may lead to HIV-1-associated dementia, but neurologic deficits may not directly correlate with productive viral infection. A discordance exists between the level of histopathologic changes and the small numbers of detectable HIV-infected cells. This supports the notion that diffusible virus-induced neurotoxins are responsible, in part, for the neurological manifestations of HIV-1 infection. Moreover, this hypothesis remains likely even if far more microglial cells and astrocytes (48) are infected with HIV-1 and low-level or restricted infection results in local neurotoxic activities. Here we demonstrate that PAF is one of possibly many HIV-induced neurotoxins. This was shown by several assay systems. First, we detected PAF in an experimental model system for HIV CNS disease. The levels of PAF in our laboratory system were high but not sustained, supporting the notion of its cyclical production. Second, we confirmed the biological relevance of our in vitro observations by assay of PAF in the CSF of HIV-infected patients. Although PAF elevations were not specific for HIV infection and CNS disease, they did correlate with the onset of neurological impairment. Finally, we inoculated PAF, in concentrations similar to those found in CSF, into primary neurons. Here PAF was a potent neurotoxin. These findings, taken together, strongly suggest that PAF plays a role in ADC. Moreover, the data provide the identity of a soluble neurotoxin, distinct from a viral gene product, produced by HIV-infected cells.
PAF is a lipid mediator that initiates a large repertoire of (8, 9) . PAF has diverse effects at the cellular level, including phagocytosis, exocytosis, aggregation, chemotaxis, calcium mobilization, eicosanoid production, and superoxide production (24, 25) . These responses are mediated by G-protein-coupled receptors (24, 25) . PAF has been shown to induce transient increases in intracellular calcium in cultured neuronal cells (3, 30) . PAF can facilitate excitatory neurotransmission and glutamate release in mammalian brains (3, 5, 37, 51, 58 (23) . Indeed, inhibitors of arachidonic acid metabolites, such as dexamethasone and nordihydroguaiaretic acid, decrease TNF-a production in HIV-1-infected cultures (20) and diminish neurotoxic activities (14a). Furthermore, PAF and arachidonic acid metabolites are potent stimuli for TNF-a production. The rise in cytokines, PAF, and arachidonic acid metabolites in these HIV-1-infected cell systems correlates with neurotoxicity, suggesting that all of these factors play important roles in progressive HIV-1 CNS disease.
PAF production in HIV-1-infected monocytes was ephemeral. This was reported previously for arachidonic acid metabolites induced in gp120-stimulated monocytes (56) . Indeed, detection of PAF was difficult at later time points (hours and/or days). There are several explanations for this result, including the following: PAF biosynthesis may occur only during initial cell-to-cell contact between HIV-1-infected monocytes and astroglial cells; uninfected or infected monocytes may secrete a factor that inhibits astroglial cell-mediated biosynthesis of PAF; and enzymes important in the generation of PAF may be expressed at low levels in HIV-1-infected monocytes and astroglia but may undergo cell-to-cell transfer so that PAF biosynthesis is increased transiently (38) .
Despite the evanescent nature of PAF metabolism in these experimental conditions, the marked increase in PAF biosynthesis in the CSF of HIV-1-infected patients and the ability of PAF to stimulate TNF production suggest that PAF is biologically relevant for ADC. One of the advantages of the CSF assays is that specimens were obtained with minimal risk to the patients and likely reflected ongoing brain pathology. The level of PAF in the CSF represents the average of different rates of production and degradation of PAF in all brain areas. Thus, levels of PAF in the CSF may be different from those observed in specific neocortical areas involved in ADC. Notwithstanding this limitation, several potentially important observations were made. First, in pediatric patients, elevated PAF levels in CSF correlated with severe encephalopathy. Second, in adult patients, elevated PAF levels in CSF correlated with both immunosuppression and onset of neurological impairment (ADC stages 1 to 4). PAF was not specific for neurological manifestations of HIV infection. PAF in CSF was elevated in a variety of non-HIV diseases with CNS manifestations, demonstrating that it is not a specific marker for HIV-1-associated CNS dysfunction.
PAF produced dose-dependent neurotoxicity (Fig. 4) . Neurotoxicity associated with PAF was blocked, in part, by coincubation with the NMDA antagonist MK-801 or memantine, demonstrating that PAF can directly activate NMDA receptors with subsequent excitotoxic neuronal damage. PAF can also increase neuronal Ca2" and lead to enhanced excitatory neurotransmission through increased glutamate release (3, 5, 37, 51, 58) . In addition, recent reports have demonstrated that arachidonic acid can inhibit high-affinity glutamate uptake in synaptosomes and astrocytes (55) and potentiate NMDA receptor currents by increasing open-channel probability (41 The ability of NMDA antagonists to block neurotoxicity has been a central feature in other models of HIV-1-mediated neuronal damage (21, 35) . The consequences of productive HIV-1 infection, including viral gene products, e.g., gpl20, may stimulate arachidonic acid metabolite and cytokine production in macrophages (56) . These alterations in macrophage secretory function may, in turn, result in neurotoxicity and support, for the first time, commonality among mechanisms for HIV-1 neuropathogenesis.
